Pharma and Biotech
Period Ending | Period | Revenue (£m) | Pre-tax (£m) | EPS | Dividend |
---|---|---|---|---|---|
31-Dec-23 | Q1 | 40.47 | (7.19) | (1.03)p | n/a |
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
30-Sep-19 | 124.01 | (58.48) | (10.72)p | n/a | n/a | n/a | n/a | 0.0% |
30-Sep-20 | 105.57 | (22.57) | (3.80)p | n/a | n/a | n/a | n/a | 0.0% |
30-Sep-21 | 125.06 | (9.18) | (1.93)p | n/a | n/a | n/a | n/a | 0.0% |
30-Sep-22 | 157.71 | (21.38) | (4.34)p | n/a | n/a | n/a | n/a | 0.0% |
30-Sep-23 | 169.48 | (12.69) | (2.41)p | n/a | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
30-Sep-24 | 179.90 | 7.70 | (0.10)p | n/a | n/a | n/a | n/a | 0.0% |
30-Sep-25 | 200.70 | 16.25 | 1.06p | 43.1 | n/a | n/a | n/a | 0.0% |
30-Sep-26 | 225.13 | 31.33 | 2.89p | 15.7 | 0.1 | +174% | n/a | 0.0% |
Copyright © 2024 FactSet Research Systems Inc. All rights reserved.
5 Yr High | 5 Yr Low | 5 Yr Avg | Curr / Avg | |
---|---|---|---|---|
Latest | n/a | n/a | n/a | 0 |
Find out about IFRS and how this affects the financial infomation for all UK companies.
Currency | UK Pounds |
Share Price | 45.50p |
Change Today | -0.50p |
% Change | -1.09 % |
52 Week High | 47.30 |
52 Week Low | 34.00 |
Volume | 770 |
Shares Issued | 739.67m |
Market Cap | £336.55m |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 2 |
Buy | 1 |
Neutral | 1 |
Sell | 0 |
Strong Sell | 0 |
Total | 4 |
No dividends found |
Time | Volume / Share Price |
10:48 | 748 @ 45.28p |
08:22 | 22 @ 45.01p |
Chair | Peter George |
CFO | Septima Maguire |
CEO | Trond Williksen |
You are here: research